Navidea Biopharmaceuticals, Inc. (NAVB) News

Navidea Biopharmaceuticals, Inc. (NAVB): $0.67

-0.06 (-7.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NAVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 493

in industry

Filter NAVB News Items

NAVB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NAVB News Highlights

  • For NAVB, its 30 day story count is now at 2.
  • Over the past 4 days, the trend for NAVB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • PENN are the most mentioned tickers in articles about NAVB.

Latest NAVB News From Around the Web

Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

Navidea Biopharmaceuticals Announces Research Agreement with the University of Pennsylvania Evaluating Tc99m Tilmanocept as a Prognostic Marker for Glioblastoma

DUBLIN, Ohio, February 07, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the signing of a Sponsored Research Agreement with the University of Pennsylvania ("Penn") for a project to evaluate the use of Tc99m tilmanocept imaging in glioblastoma as a prognostic agent for tumor growth rate and overall survival. The research is led by Principal

Yahoo | February 7, 2022

Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American

DUBLIN, Ohio, February 03, 2022--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced settlement of the ongoing litigation with Platinum-Montaur Life Sciences LLC ("Platinum-Montaur"), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Capital Opportunity Fund, Platinum Partners Liquid Opportuni

Yahoo | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | January 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We've reached the halfway point of the week and we're starting it with an overview of the biggest pre-market stock movers for Wednesday!

William White on InvestorPlace | December 22, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | December 16, 2021

Navidea Biopharmaceuticals Announces Launch of Phase 3 Clinical Trial in Rheumatoid Arthritis

DUBLIN, Ohio, December 16, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the launch of the NAV3-33 Phase 3 clinical trial titled "Evaluation of Tc99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA)."

Yahoo | December 16, 2021

Navidea Shares Gain After Terminating Stock Purchase Agreement

Navidea Biopharmaceuticals Inc (NYSE: NAVB) has terminated the Stock Purchase Agreement executed on August 30, 2020. The investors agreed to purchase up to $25.0 million in shares of Navidea. The initial closings were to occur within forty-five (45) business days. The investors agreed to purchase an aggregate of 1 million shares at $5.00 per share. To date, the Company has received only $25,000 of the $5.0 million that was due at the initial closing. On Tuesday, the Company notified the Investor

Yahoo | December 16, 2021

Navidea Biopharmaceuticals Completes Full Enrollment in Phase 2b Normative Database Study to Support its Rheumatoid Arthritis Program

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has achieved full enrollment in its NAV3-35 Phase 2b clinical study titled Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging with Tc99m Tilmanocept. Establishing a healthy subject database is necessary to create a quantitative method f

Business Wire | December 15, 2021

Navidea Biopharmaceuticals Terminates Stock Purchase Agreement

DUBLIN, Ohio, December 15, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has terminated the Stock Purchase Agreement that was executed on August 30, 2020.

Yahoo | December 15, 2021

Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the results of a third-party asset valuation of its Rheumatoid Arthritis (“RA”) diagnostic product candidate. The Company engaged the independent third-party valuation firm, LifeSci Partners

Wallstreet:Online | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5675 seconds.